In this issue:
Age at diabetes onset and risk of PC
STNM01 as second-line therapy for PC
18-Fluoride positron emission tomography and PDAC diagnosis
Recurrence and outcomes of pancreatic neuroendocrine tumours
S-1 chemotherapy and OS in PC
OS of FOLFIRINOX chemotherapy in BRPC and LAPC
Biological age in elderly PC patients
Nal-IRI use for metastatic PC
OS of cancer survivors with new PC diagnosis
FOLFIRINOX gemcitabine/nabpaclitaxel in advanced PDAC
Please login below to download this issue (PDF)